Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
MVA-BN was globally well tolerated despite higher reactogenicity for the ID than the SC route, especially for the reactions at the local injection site. The ID dose-sparing strategy was proven safe and immunogenic and would make vaccination available to more people. Our data support the current WHO recommendation of using the ID route in low-medium-income countries (LMIC), although response data in people infected with the new 1b clade are urgently needed.
Authors
- Germana Grassi (ORCID: https://orcid.org/0000-0001-8168-8721)
- Francesca Colavita (ORCID: https://orcid.org/0000-0003-0640-8667)
- Giulia Del Duca (ORCID: https://orcid.org/0009-0004-3408-3817)
- Miriam Lichtner (ORCID: https://orcid.org/0000-0002-7730-3953)
- Roberta Gagliardini (ORCID: https://orcid.org/0000-0002-6351-2623)
- Claudia Cimaglia (ORCID: https://orcid.org/0000-0001-6949-3876)
- Jessica Paulicelli (ORCID: https://orcid.org/0009-0008-8361-9605)
- Francesco Vaia
- Loredana Sarmati (ORCID: https://orcid.org/0000-0003-1452-0333)
- Carla Fontana (ORCID: https://orcid.org/0000-0003-2198-1947)
- Rita Casetti (ORCID: https://orcid.org/0000-0002-7574-8780)
- Stefania Notari (ORCID: https://orcid.org/0000-0002-7692-6606)
- Claudio Maria Mastroianni (ORCID: https://orcid.org/0000-0002-1286-467X)
- Andrea Antinori (ORCID: https://orcid.org/0000-0003-2121-4684)
- Alessandra Oliva (ORCID: https://orcid.org/0000-0003-0832-7975)
- Alessandra Latini (ORCID: https://orcid.org/0000-0002-9421-6560)
- Paolo Faccendini
- Rozenn Esvan (ORCID: https://orcid.org/0000-0001-6127-0045)
- Fabrizio Maggi (ORCID: https://orcid.org/0000-0001-7489-5271)
- Silvia Meschi (ORCID: https://orcid.org/0000-0003-0924-993X)
- Alessandro Cozzi‐Lepri (ORCID: https://orcid.org/0000-0002-6339-919X)
- Emanuele Nicastri (ORCID: https://orcid.org/0000-0002-5606-8712)
- Enrica Tamburrini (ORCID: https://orcid.org/0000-0003-4930-426X)
- Pierluca Piselli (ORCID: https://orcid.org/0000-0002-7342-0263)
- Licia Bordi (ORCID: https://orcid.org/0000-0003-3962-3646)
- Valentina Mazzotta (ORCID: https://orcid.org/0000-0002-0240-7504)
- Giulia Micheli (ORCID: https://orcid.org/0000-0001-7996-8345)
- Eleonora Cimini (ORCID: https://orcid.org/0000-0002-2659-0868)
- Alessandro Caioli (ORCID: https://orcid.org/0000-0003-2097-9116)
- Giulia Matusali (ORCID: https://orcid.org/0000-0002-2948-4243)
- Enrico Girardi (ORCID: https://orcid.org/0000-0001-8182-5896)
- Andrea Siddu (ORCID: https://orcid.org/0000-0001-8212-3538)
- Alessandra Barca (ORCID: https://orcid.org/0000-0002-6747-269X)
- Alessandro Giacinta
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Rome Tor Vergata (IT)
- Ministero della Salute (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Ospedale Santa Maria Goretti (IT)
- San Gallicano Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Regione Lazio
- University College London (GB)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Vaccines
- Published
- 2024-12-31
- DOI
- https://doi.org/10.3390/vaccines13010032
- Citations
- 5
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Ministero della Salute